• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人源抗体治疗药物的聚集、稳定性和制剂。

Aggregation, stability, and formulation of human antibody therapeutics.

机构信息

MedImmune, Cambridge, UK.

出版信息

Adv Protein Chem Struct Biol. 2011;84:41-61. doi: 10.1016/B978-0-12-386483-3.00004-5.

DOI:10.1016/B978-0-12-386483-3.00004-5
PMID:21846562
Abstract

Many human monoclonal antibodies display poor biophysical properties, such as low stability and a propensity to aggregate. These unfavorable tendencies can be even more pronounced for human antibody fragments, which often require a considerable degree of optimization. In this review, we describe methods for analyzing aggregation and stability of human antibodies and antibody fragments. We also provide an overview of recent approaches to improve these properties through engineering and formulation.

摘要

许多人源单克隆抗体表现出较差的物理化学性质,例如低稳定性和易于聚集的倾向。对于人源抗体片段而言,这些不利趋势可能更为明显,因为它们通常需要相当程度的优化。在本文中,我们描述了分析人源抗体和抗体片段聚集和稳定性的方法。我们还概述了通过工程改造和制剂来改善这些性质的最新方法。

相似文献

1
Aggregation, stability, and formulation of human antibody therapeutics.人源抗体治疗药物的聚集、稳定性和制剂。
Adv Protein Chem Struct Biol. 2011;84:41-61. doi: 10.1016/B978-0-12-386483-3.00004-5.
2
Stability engineering of the human antibody repertoire.人类抗体库的稳定性工程。
FEBS Lett. 2014 Jan 21;588(2):269-77. doi: 10.1016/j.febslet.2013.11.029. Epub 2013 Nov 28.
3
Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.糖基化对治疗性单克隆抗体聚集倾向的影响。
Biotechnol J. 2011 Jan;6(1):38-44. doi: 10.1002/biot.201000091.
4
Toward aggregation-resistant antibodies by design.通过设计实现抗聚集抗体。
Trends Biotechnol. 2013 Nov;31(11):612-20. doi: 10.1016/j.tibtech.2013.07.002. Epub 2013 Aug 7.
5
Prediction and Reduction of the Aggregation of Monoclonal Antibodies.单克隆抗体聚集的预测与减少
J Mol Biol. 2017 Apr 21;429(8):1244-1261. doi: 10.1016/j.jmb.2017.03.014. Epub 2017 Mar 18.
6
Aggregates in monoclonal antibody manufacturing processes.单克隆抗体生产工艺中的聚集物。
Biotechnol Bioeng. 2011 Jul;108(7):1494-508. doi: 10.1002/bit.23155. Epub 2011 Apr 20.
7
Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding.用 ANS 和 Thioflavin T 结合研究治疗性单克隆抗体的构象稳定性和聚集。
MAbs. 2011 Jul-Aug;3(4):408-11. doi: 10.4161/mabs.3.4.15677. Epub 2011 Jul 1.
8
Boosting antibody developability through rational sequence optimization.通过合理的序列优化提高抗体的可开发性。
MAbs. 2015;7(3):505-15. doi: 10.1080/19420862.2015.1017695.
9
Mutational approaches to improve the biophysical properties of human single-domain antibodies.改善人单域抗体生物物理特性的突变方法。
Biochim Biophys Acta. 2014 Nov;1844(11):1983-2001. doi: 10.1016/j.bbapap.2014.07.008. Epub 2014 Jul 24.
10
High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.高通量评估单克隆抗体制剂的热稳定性和胶体稳定性参数。
J Pharm Sci. 2011 Dec;100(12):5126-41. doi: 10.1002/jps.22712. Epub 2011 Jul 24.

引用本文的文献

1
CDR clipping-induced heterodimerization: identification of a novel dimerization mechanism in a co-formulated antibody cocktail via a multifaceted mass spectrometry approach.互补决定区(CDR)剪切诱导的异源二聚化:通过多方面质谱方法鉴定共同配制的抗体混合物中的一种新型二聚化机制。
MAbs. 2025 Dec;17(1):2546074. doi: 10.1080/19420862.2025.2546074. Epub 2025 Aug 14.
2
AggNet: Advancing protein aggregation analysis through deep learning and protein language model.AggNet:通过深度学习和蛋白质语言模型推进蛋白质聚集分析。
Protein Sci. 2025 Feb;34(2):e70031. doi: 10.1002/pro.70031.
3
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate.
解析辅料稳定治疗性蛋白的机制:精氨酸和谷氨酸两种单克隆抗体的案例研究
MAbs. 2024 Jan-Dec;16(1):2427771. doi: 10.1080/19420862.2024.2427771. Epub 2024 Nov 14.
4
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.双特异性抗体治疗实体瘤的临床进展与挑战。
Mol Diagn Ther. 2024 Nov;28(6):669-702. doi: 10.1007/s40291-024-00734-w. Epub 2024 Aug 22.
5
A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications.双特异性抗体在发现阶段的可制造性评估与优化案例研究及其启示
Antib Ther. 2024 May 29;7(3):189-198. doi: 10.1093/abt/tbae013. eCollection 2024 Jul.
6
Stability of Protein Pharmaceuticals: Recent Advances.蛋白质类药物的稳定性:最新进展
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
7
A Regulatory Perspective on Biosimilar Medicines.生物类似药的监管视角
Pharmaceutics. 2024 Feb 25;16(3):321. doi: 10.3390/pharmaceutics16030321.
8
Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry.通过尺寸排阻色谱法结合天然质谱法评估抗体片段对完整分子聚集的影响。
MAbs. 2024 Jan-Dec;16(1):2334783. doi: 10.1080/19420862.2024.2334783. Epub 2024 Mar 27.
9
Internal Fragments Enhance Middle-Down Mass Spectrometry Structural Characterization of Monoclonal Antibodies and Antibody-Drug Conjugates.内部片段增强了单克隆抗体和抗体药物偶联物的中自上而下质谱结构表征。
Anal Chem. 2024 Feb 13;96(6):2491-2499. doi: 10.1021/acs.analchem.3c04526. Epub 2024 Jan 31.
10
Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.开发一种新型噬菌体展示人 scFv 文库标记[89Zr]Zr 的人源抗体。
Clin Cancer Res. 2024 Apr 1;30(7):1293-1306. doi: 10.1158/1078-0432.CCR-23-3647.